Why Eli Lilly Stock is the ‘Nvidia’ of GLP-1 Meds
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
- Latest
- Trending
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Automated insulin delivery tech helps T1D runners manage glucose during marathons, enhancing safety and performance.
S&P 500 drops 2% amid weak manufacturing. Molson Coors gains as stock markets react to economic signals.
Stifel downgrades Medtronic to 'Hold' due to slow growth in key initiatives like HUGO system, affecting market competitiveness.
Federal push to harness AI in medical research relies on extensive data collection and privacy safeguards.
Trinity Biotech will release its Q2 2024 financial results on August 14, 2024, with a call at 8:30 AM ET ...
Lilly's new Boston facility enhances RNA/DNA research, hosting 500 scientists and expanding Gateway Labs to the East Coast.
The S&P 500 gained 0.5% amid stock market fluctuations, with notable gains for Expedia and Akamai, despite macro concerns.
Trinity Biotech has until October 31, 2024, to meet the Nasdaq MVPHS requirement, securing a chance to maintain its listing.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.